嗜铬细胞瘤和副神经节瘤遗传学和基因诊断的研究进展

兰卫华; 蓝保华; 刘秋礼; 江军

doi:10.13201/j.issn.1001-1420.2019.12.020

嗜铬细胞瘤和副神经节瘤遗传学和基因诊断的研究进展

- 1. 陆军军医大学大坪医院泌尿外科(重庆, 400042);
- 2. 重庆市九龙坡区人民医院肿瘤科

详细信息

通讯作者: 江军,E-mail:jiangjun_64@163.com

中图分类号: R736.6

收稿日期: 2018-06-23

Advancements in genetics and genetic diagnosis of pheochromocytoma and paraganglioma

- 1. Department of Urology, Daping Hospital, Army Medical University, Chongqing, 400042, China;
- 2. Department of Oncology, People's Hospital of Jiulongpo District

More Information

Corresponding author: JIANG Jun, E-mail: jiangjun_64@163.com

Received Date: 23 June 2018

摘要

摘要: 近年来，嗜铬细胞瘤和副神经节瘤（PPGL）遗传学方面的进展主要是它的高遗传性的发现、愈来愈多易感基因的鉴定及其不同基因型与临床表型之间关系的不断明晰等。因此，目前推荐对所有PPGL患者进行基因检测；不同个体患者的临床表现，有助于指导基因检测方案的优化和检测成本的控制；通过基因检测了解疾病的基因基础不仅可以加深对该病的理解，而且有助于对患者及其家属进行个体化诊断、治疗和随访。本文主要对新近PPGL遗传学研究和基因检测方面的研究进展作一综述。
- 嗜铬细胞瘤 /
- 副神经节瘤 /
- 遗传学 /
- 基因检测
Abstract: In recent years, the research progress in genetics of pheochromocytoma and paraganglioma(PPGL) mainly reflected in the discovery of its high heritability, identification of more and more susceptibility genes and persistent establishment of relation between the distinct genotypes and phenotypes. Therefore, genetic testing is currently recommended for all the patients with PPGL. Clinical manifestations of individual patients will help for optimization of the testing protocol and controlling of testing costs. Knowledge of genetic basis of PPGL through genetic testing can both deepen understanding of the disease and favor the individualized diagnosis, treatment and follow-up of the patients and their family members. Herein we reviewed recent studies in the field of PPGL genetics and genetic diagnosis.
- pheochromocytoma /
- paraganglioma /
- genetics /
- genetic testing

HTML全文

参考文献(50)

[1]	Benn D E, Robinson B G.Genetic basis of phaeochromocytoma and paraganglioma[J].Best Pract Res Clin Endocrinol Metab, 2006, 20(3):435-450.
[2]	Gimenez-Roqueplo A P, Burnichon N, Amar L, et al.Recent advances in the genetics of phaeochromocytoma and functional paraganglioma[J].Clin Exp Pharmacol Physiol, 2008, 35(4):376-379.
[3]	Fishbein L, Merrill S, Fraker D L, et al.Inherited mutations in pheochromocytoma and paraganglioma:why all patients should be offered genetic testing[J].Ann Surg Oncol, 2013, 20(5):1444-1450.
[4]	邓建华, 李汉忠.遗传相关的嗜铬细胞瘤/副神经节瘤的研究进展[J].临床泌尿外科杂志, 2013, 28(1):72-77.
[5]	Neumann H P, Bausch B, McWhinney S R, et al.Germline mutations in nonsyndromicpheochromocytoma[J].N Engl J Med, 2002, 346(19):1459-1466.
[6]	Dahia P L.Pheochromocytoma and paraganglioma pathogenesis:learning from genetic heterogeneity[J].Nat Rev Cancer, 2014, 14(2):108-119.
[7]	NGS in PPGL(NGSnPPGL) Study Group, Toledo R A, Burnichon N, et al.Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas[J].Nat Rev Endocrinol, 2017, 13(4):233-247.
[8]	Gimenez-Roqueplo A P, Dahia P L, Robledo M.An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes[J].Horm Metab Res, 2012, 44(5):328-333.
[9]	Rana H Q, Rainville I R, Vaidya A.Genetic testing in the clinical care of patients with pheochromocytoma and paraganglioma[J].Curr Opin Endocrinol Diabetes Obes, 2014, 21(3):166-176.
[10]	King K S, Pacak K.Familial pheochromocytomas and paragangliomas[J].Mol Cell Endocrinol, 2014, 386(1-2):92-100.
[11]	Lam A K.Update on Paragangliomas and Pheochromocytomas[J].Turk Patoloji Derg, 2015, 31Suppl 1:105-112.
[12]	NGS in PPGL(NGSnPPGL) Study Group, Toledo R A, Burnichon N, et al.Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas[J].Nat Rev Endocrinol, 2017, 13(4):233-247.
[13]	Favier J, Amar L, Gimenez-Roqueplo A P.Paraganglioma and phaeochromocytoma:from genetics to personalized medicine[J].Nat Rev Endocrinol, 2015, 11(2):101-111.
[14]	López-Jiménez E, Gómez-López G, Leandro-García L J, et al.Research resource:Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas[J].Mol Endocrinol, 2010, 24(12):2382-2391.
[15]	Gottfried O N, Viskochil D H, Couldwell W T.Neurofibromatosis Type 1and tumorigenesis:molecular mechanisms and therapeutic implications[J].Neurosurg Focus, 2010, 28(1):E8.
[16]	Eisenhofer G, Lenders J W, Timmers H, et al.Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma[J].Clin Chem, 2011, 57(3):411-420.
[17]	Bausch B, Borozdin W, Mautner V F, et al.Germline NF1mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1[J].J Clin Endocrinol Metab, 2007, 92(7):2784-2792.
[18]	Eisenhofer G, Timmers H J, Lenders J W, et al.Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location[J].J Clin Endocrinol Metab, 2011, 96(2):375-384.
[19]	Mannelli M, Castellano M, Schiavi F, et al.Clinically guided genetic screening in a large cohort of italian patients with pheochromocytomas and/or functional or nonfunctional paragangliomas[J].J Clin Endocrinol Metab, 2009, 94(5):1541-1547.
[20]	Pacak K, Eisenhofer G, Ilias I.Diagnosis of pheochromocytoma with special emphasis on MEN2syndrome[J].Hormones(Athens), 2009, 8(2):111-116.
[21]	Qin Y, Yao L, King E E, et al.Germline mutations in TMEM127confer susceptibility to pheochromocytoma[J].Nat Genet, 2010, 42(3):229-233.
[22]	Burnichon N, Lepoutre-Lussey C, Laffaire J, et al.A novel TMEM127mutation in a patient with familial bilateral pheochromocytoma[J].Eur J Endocrinol, 2011, 164(1):141-145.
[23]	Neumann H P, Sullivan M, Winter A, et al.Germline mutations of the TMEM127gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites[J].J Clin Endocrinol Metab, 2011, 96(8):E1279-E1282.
[24]	Hernandez K G, Ezzat S, Morel C F, et al.Familial pheochromocytoma and renal cell carcinoma syndrome:TMEM127as a novel candidate gene for the association[J].Virchows Arch, 2015, 466(6):727-732.
[25]	Comino-Méndez I, Gracia-Aznárez F J, Schiavi F, et al.Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma[J].Nat Genet, 2011, 43(7):663-667.
[26]	Peczkowska M, Kowalska A, Sygut J, et al.Testing new susceptibility genes in the cohort of apparently sporadic phaeochromocytoma/paraganglioma patients with clinical characteristics of hereditary syndromes[J].Clin Endocrinol(Oxf), 2013, 79(6):817-823.
[27]	Burnichon N, Cascón A, Schiavi F, et al.MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma[J].Clin Cancer Res, 2012, 18(10):2828-2837.
[28]	Maher E R, Neumann H P, Richard S.von Hippel-Lindau disease:a clinical and scientific review[J].Eur JHum Genet, 2011, 19(6):617-623.
[29]	Burnichon N, Brière J J, LibéR, et al.SDHA is a tumor suppressor gene causing paraganglioma[J].Hum Mol Genet, 2010, 19(15):3011-3020.
[30]	Korpershoek E, Favier J, Gaal J, et al.SDHA immunohistochemistry detects germline SDHA gene mutations in apparently sporadic paragangliomas and pheochromocytomas[J].J Clin Endocrinol Metab, 2011, 96(9):E1472-E1476.
[31]	Ricketts C J, Forman J R, Rattenberry E, et al.Tumor risks and genotype-phenotype-proteotype analysis in358patients with germline mutations in SDHB and SDHD[J].Hum Mutat, 2010, 31(1):41-51.
[32]	Neumann H P, Pawlu C, Peczkowska M, et al.Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations[J].JAMA, 2004, 292(8):943-951.
[33]	Schiavi F, Boedeker C C, Bausch B, et al.Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene[J].JAMA, 2005, 294(16):2057-2063.
[34]	Müller U, Troidl C, Niemann S.SDHC mutations in hereditary paraganglioma/pheochromocytoma[J].Fam Cancer, 2005, 4(1):9-12.
[35]	Burnichon N, Rohmer V, Amar L, et al.The succinate dehydrogenase genetic testing in a large prospective series of patients with paragangliomas[J].J Clin Endocrinol Metab, 2009, 94(8):2817-2827.
[36]	Bickmann J K, Sollfrank S, Schad A, et al.Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas:lessons from three unrelated cases with an identical germline mutation(p.Arg133*)[J].J Clin Endocrinol Metab, 2014, 99(3):E489-E496.
[37]	Kunst H P, Rutten M H, de M9nnink J P, et al.SDHAF2(PGL2-SDH5) and hereditary head and neck paraganglioma[J].Clin Cancer Res, 2011, 17(2):247-254.
[38]	Bayley J P, Kunst H P, Cascon A, et al.SDHAF2mutations in familial and sporadic paraganglioma and phaeochromocytoma[J].Lancet Oncol, 2010, 11(4):366-372.
[39]	Hao H X, Khalimonchuk O, Schraders M, et al.SDH5, agene required for flavination of succinate dehydrogenase, is mutated in paraganglioma[J].Science, 2009, 325(5944):1139-1142.
[40]	李涛, 李学超, 吴清剑, 等.散发性嗜铬细胞瘤SDH5基因2号外显子突变分析[J].临床泌尿外科杂志, 2014, 29(12):1091-1093.
[41]	Castro-Vega L J, Buffet A, De Cubas A A, et al.Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas[J].Hum Mol Genet, 2014, 23(9):2440-2446.
[42]	Pacak K, Jochmanova I, Prodanov T, et al.New syndrome of paraganglioma and somatostatinoma associated with polycythemia[J].J Clin Oncol, 2013, 31(13):1690-1698.
[43]	Zhuang Z, Yang C, Lorenzo F, et al.Somatic HIF2Again-of-function mutations in paraganglioma with polycythemia[J].N Engl J Med, 2012, 367(10):922-930.
[44]	Yang C, Sun M G, Matro J, et al.Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas[J].Blood, 2013, 121(13):2563-2566.
[45]	Buffet A, Smati S, Mansuy L, et al.Mosaicism in HIF2A-related polycythemia-paragangliomasyndrome[J].J Clin Endocrinol Metab, 2014, 99(2):E369-E373.
[46]	Lorenzo F R, Yang C, Ng Tang Fui M, et al.A novel EPAS1/HIF2Agermline mutation in a congenital polycythemia with paraganglioma[J].J Mol Med(Berl), 2013, 91(4):507-512.
[47]	Lenders J W, Duh Q Y, Eisenhofer G, et al.Pheochromocytoma and paraganglioma:an endocrine society clinical practice guideline[J].J Clin Endocrinol Metab, 2014, 99(6):1915-1942.
[48]	Liu Q, Tong D, Yuan W, et al.Different RET gene mutation-induced multiple endocrine neoplasia type 2Ain 3Chinese families[J].Medicine(Baltimore), 2017, 6(3):e5967.
[49]	Liu Q, Yuan G, Tong D, et al.Novel Genotype-Phenotype Correlations in Five Chinese Families with Von Hippel-Lindau Disease[J].Endocr Connect, 2018, 7(7):870-878.
[50]	Gill A J, Benn D E, Chou A, et al.Immunohistochemistry for SDHB triages genetic testing of SDHB, SDHC, and SDHD in paraganglioma-pheochromocytomasyndromes[J].Hum Pathol, 2010, 41(6):805-814.